Abstract 25P
Background
With the advent of novel antibody-drug conjugate (ADC), an emerging subgroup of human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized which may take advantage from the anti-tumor activity. We took advantage of Taiwan Cancer Registry (TCR) to evaluate the clinical presentations and prognostication for HER2-low breast cancer.
Methods
HER2-low breast cancers were defined operationally with HER2 immunohistochemistry (IHC) 1+ or 2+ with a negative fluorescence in situ hybridization (FISH) while HER2-zero defined with an IHC score 0. Breast cancer index cases (n=189465) from TCR between 2007 and 2017 were reduced to 133546 sides of breast cancer per subject. Clinical features such as IHC test, stage, grade and outcomes such as relapse-free and overall survival were compared between HER2-low and HER2-zero.
Results
The safety analysis group comprised 37195 HER2-negative breast cancers, including 14288 IHC 1+, 10486 FISH-negative, 8907 IHC 0 and 3323 IHC 2+/FISH-undetermined cases. Among HER2-negative breast cancers, the proportion of HER2-low and HER2-zero was 68.9% and 31.1%, respectively, after excluding HER2 ambiguity. Overall survival was 95.7% versus 95.9% for HER2-low and HER2-zero breast cancers, which was 94.1% and 94.7% for relapse-free survival. The distributions of pathological stages from 0 to IV were 6.7%, 41.5%, 38.5%, 13.1% and 0.3% for HER2-low and were 8.5%, 42.8%, 37.5%, 11% and 0.4% for HER2-zero breast cancers. Regarding estrogen receptor (ER) and progesterone receptor (PR) status, 87.6% and 80.9% of the HER2-low cases were ER+ and PR+ while 81.9% and 74.8% of the HER2-zero patients were ER+ and PR+. High or poorly differentiated grade was reported from 23.4% of HER2-low and 25.5% of HER2-zero breast cancers. The diagnosed age was 54 versus 54.3 between HER2-low and HER2-zero breast cancers (P=0.02).
Conclusions
HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LMT.
Funding
Melissa Lee Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract